retatrutide phase 2 study results VisualAbstract: reduces body weight by 17.5% in patients with obesity This week's most cited articles:

By integrating thoughtful lifestyle support and leveraging digital tools, life sciences companies can redefine obesity care, ensuring patients achieve sustainable health outcomes while differentiating their brands in a rapidly evolving market

Multiple cardiovascular outcomes trials (CVOTs) have shown significant reductions in major adverse cardiovascular events (MACE), which typically includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke

However, when starting a GLP-1 agonist in someone already on basal insulin, the insulin dose often needs to be reduced by 10 to 20 percent to prevent hypoglycemia

Diarrhea occurs in approximately 30% of patients taking semaglutide 2.4 mg (Wegovy) and 19-23% of patients taking tirzepatide (Zepbound) according to FDA prescribing information

one bottle gives margin for replacement draws

Recommendation for oral semaglutide (Wegovy pill, Rybelsus): Avoid breastfeeding